Drug Combination Details
| General Information of the Combination (ID: C14937) | |||||
|---|---|---|---|---|---|
| Name | Scutellarin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Platinum-DNA adducts | ||||
| Up-regulation | Ratio of Bax to Bcl-2 | |||||
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Scutellarin synergistically enhances cisplatin effect against ovarian cancer cells through enhancing the ability of cisplatin binding to DNA. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Biological
Regulation |
Prevention | BamH1 digestion on pBR322 plasmid DNA | ||||
| Up-regulation | Extent of platinum-DNA adducts | |||||
| Up-regulation | Ratio of Bax to Bcl-2 | |||||
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Scutellarin synergistically enhances cisplatin effect against ovarian cancer cells through enhancing the ability of cisplatin binding to DNA. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MET | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | A549/DDP-Luc cells (4*106) were subcutaneously injected into the right flank of 4-to-6 week-old female BALB/c nude mice. | |||||
| Experimental
Result(s) |
Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways. | |||||
